Core Viewpoint - Junshi Biosciences has received approval for clinical trials of JS207 (PD-1/VEGF dual antibody) and JS212 (EGFR/HER3 dual antibody ADC) and plans to initiate related clinical research soon [1] Group 1: Clinical Trials - The company is currently conducting Phase II clinical trials for JS207, exploring combinations with chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types [1] - The company aims to explore various combination therapies to maximize the synergistic effects of its pipeline [1] Group 2: Development Challenges - The lengthy and complex process of drug development, from research to clinical trial approval and production, is subject to various uncertainties [1]

Core Viewpoint - The company has received approval for the clinical trials of JS207 (PD-1/VEGF dual antibody) and JS212 (EGFR/HER3 dual antibody ADC) in combination, and plans to initiate these studies soon [1] Group 1: Clinical Trials - The company has obtained approval for the I/II phase clinical trials of the combination of JS207 and JS212 [1] - JS207 is currently in the II phase of clinical research, exploring combinations with chemotherapy, monoclonal antibodies, ADCs, and other drugs across multiple tumor types [1] - The company aims to actively explore various combination therapies to maximize the synergistic effects of its pipeline [1] Group 2: Research and Development Challenges - The development of pharmaceutical products involves a lengthy process with multiple stages, making it susceptible to various uncertainties [1]